期刊
PHYSIOLOGICAL REVIEWS
卷 101, 期 3, 页码 797-855出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/physrev.00012.2019
关键词
bisphosphonate; denosumab; dormancy; immunosurveillance; metastatic niche
类别
资金
- Inserm
- Inserm Cancer
- University of Lyon
- French National Cancer Institute (INCa) [PLBIO14-164, PLBIO14-213]
- Weston Park Cancer Charity [CA 142, CA175, CA163]
- LabEX DEVweCAN from Universite de Lyon, within the program Investissements d'Avenir [ANR-11-IDEX-0007, ANR-10-LABX-61]
- Research Council UK [MR/P000096/1]
- Appel a Projets LIA/LEA 2016 [ASC17018CSA]
- MRC [MR/P000096/1] Funding Source: UKRI
Skeletal metastases are common complications of many cancers, significantly impacting patients' quality of life. The multistage process of bone metastasis involves various cellular and molecular mechanisms. While existing bone-targeted agents have made progress, further research and more effective treatment options are still needed.
Skeletal metastases are frequent complications of many cancers, causing bone complications (fractures, bone pain, disability) that negatively affect the patient's quality of life. Here, we first discuss the burden of skeletal complications in cancer bone metastasis. We then describe the pathophysiology of bone metastasis. Bone metastasis is a multistage process: long before the development of clinically detectable metastases, circulating tumor cells settle and enter a dormant state in normal vascular and endosteal niches present in the bone marrow, which provide immediate attachment and shelter, and only become active years later as they proliferate and alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. The molecular mechanisms involved in mediating each of these steps are described, and we also explain how tumor cells interact with a myriad of interconnected cell populations in the bone marrow, including a rich vascular network, immune cells, adipocytes, and nerves. We discuss metabolic programs that tumor cells could engage with to specifically grow in bone. We also describe the progress and future directions of existing bone-targeted agents and report emerging therapies that have arisen from recent advances in our understanding of the pathophysiology of bone metastases. Finally, we discuss the value of bone turnover biomarkers in detection and monitoring of progression and therapeutic effects in patients with bone metastasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据